Search clinical trials for: 89Zr-KN035

Total 128 results

The First Affiliated Hospital of Soochow University
MITRO Biotech Co., Ltd.

Unknown

89Zr-KN035 PET Imaging in Patients With Advanced Solid Tumors

Solid Tumor, Adult

China
Wuxi No. 4 People's Hospital

Unknown

89Zr-labeled KN035 PET Imaging in Patients With PD-L1 Positive Solid Tumors

Solid Tumor, Adult

China
3D Medicines (Sichuan) Co., Ltd.

Recruiting

KN035 for dMMR/MSI-H Advanced Solid Tumors

Solid Tumor

China
RenJi Hospital

Unknown

KN035 in Patients With Advanced Multiple Primary Tumors (CPOG035-01)

Multiple Primary Neoplasm

China
Northern Jiangsu Province People's Hospital

Recruiting

A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer

NSCLC

China
Telix International Pty Ltd

Completed

89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study (89ZR-TLX250)

Clear Cell Renal Cell Carcinoma

United Kingdom, United States, Australia, Turkey, Netherlands, Belgium, Canada, France
Telix International Pty Ltd

Completed

Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC (ZIRDAC-JP)

Carcinoma, Renal Cell | Clear Cell Renal Cell Carcinoma

Japan
Telix International Pty Ltd
Grand Pharmaceutical (China) Co., Ltd.

Completed

Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma (ZIRDOSE-CP)

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Cancer | Suspected Recurrent Renal Clear Cell Carcinoma

China
Chipscreen Biosciences, Ltd.

Active, not recruiting

Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.

Non Small Cell Lung Cancer

China
3D Medicines (Sichuan) Co., Ltd.

Completed

A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

Japan
3D Medicines (Sichuan) Co., Ltd.

Completed

Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors

Solid Tumors

United States
3D Medicines (Sichuan) Co., Ltd.

Completed

Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors

Solid Tumors

China
Affiliated Hospital of Jiangnan University

Recruiting

89Zr-labeled NY008 PET Imaging in Patients

Multiple Myeloma

China
Wuxi No. 4 People's Hospital

Not yet recruiting

Safety Study of 89Zr-Anti-CLDN18.2 mAbs PET Imaging in Patients With CLDN18.2 Positive Solid Tumors

Solid Tumor, Adult

China
South Metropolitan Health Service
Telix Pharmaceuticals (Innovations) Pty Limited

Completed

Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Patients (ZiPUP)

Urothelial Carcinoma

Australia
Radboud University Medical Center
ABX CRO; Telix International Pty Ltd

Completed

89Zr-girentuximab ) Dosimetry in CCRC Study - ZIR-DOSE

Clear Cell Renal Carcinoma

Netherlands
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Completed

Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer

Prostate Cancer

United States
Telix International Pty Ltd

Recruiting

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Soft Tissue Sarcoma | Cervical Cancer | Nasopharyngeal Carcinoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Glioblastoma Multiforme | Non Small Cell Lung Cancer | Cholangiocarcinoma | Epithelial Ovarian Cancer | Head and Neck Squamous Cell Carcinoma and other conditions

United States
Boehringer Ingelheim

Recruiting

A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

Melanoma | Non-small Cell Lung Cancer (NSCLC) | Carcinoma, Squamous Cell of Head and Neck (HNSCC)

Netherlands
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Neoadjuvant Treatment For Locally Advanced Thymic Cancer

Thymic Carcinoma

China
Affiliated Hospital of Jiangnan University

Recruiting

89Zr-labeled NY009 PET Imaging in Patients

Cancer

China
Sinotau Pharmaceutical Group

Not yet recruiting

Clinical Study on PET Imaging, Distribution and PK of 89Zr-CD147 in Patients With Solid Tumors

Solid Tumor
Robert Flavell, MD, PhD

Suspended

Zr-89 Cimzia PET Imaging Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Wuxi No. 4 People's Hospital

Not yet recruiting

Safety Study of 89Zr-NY001 PET Imaging in Patients

Solid Tumor, Adult

China
Huashan Hospital

Unknown

The Research on 89Zr-ABT806 PET Imaging in High Grade Glioma

Glioma

China
University Medical Center Groningen
Genentech, Inc.; Amsterdam UMC, location VUmc

Completed

89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients (MMOT)

Digestive System Diseases | Ovarian Diseases | Adnexal Diseases | Digestive System Neoplasms | Pancreatic Neoplasms | Ovarian Neoplasms | Pancreatic Diseases

Netherlands
Telix Pharmaceuticals (Innovations) Pty Limited

Available

89Zr-DFO-girentuximab Expanded Access Program (EAP)

Clear Cell Renal Cell Carcinoma

United States
ImaginAb, Inc.

Completed

Comparison of PET With [89Zr]-Df-IAb2M and [111In]-Capromab Pendetide in the Detection of Prostate Cancer Pre-Prostatectomy

Prostate Cancer

United States
ImaginAb, Inc.

Completed

Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer (IAB2M)

Metastatic Prostate Cancer

United States
ImaginAb, Inc.

Withdrawn

A Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer

Prostate Cancer

United States
Université de Sherbrooke
Eli Lilly and Company; Chorus Wellness Inc.; AL-S Pharma AG

Recruiting

Safety and Dosimetry of a New Radiotracer to Detect Misfolded SOD1 Associated With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

Canada
Institut Cancerologie de l'Ouest
ATONCO

Completed

Assessment of safEty, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled giRenTuximab (89Zr-Girentuximab) in patIents With Non-musclE-iNvasive Bladder CancEr (NMIBC) (PERTINENCE)

Bladder Cancer

France
ImaginAb, Inc.

Recruiting

Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies (iPREDICT)

Melanoma | Renal Cell Carcinoma | Non Small Cell Lung Cancer | Merkel Cell Carcinoma, Unspecified

United States, Australia, Belgium, Netherlands, Switzerland, United Kingdom
University Medical Center Groningen

Completed

89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition (AUY922)

Breast Cancer

Netherlands
University Medical Center Groningen

Completed

Pembrolizumab-PET Imaging

Melanoma | Non-small Cell Lung Cancer

Netherlands
Boehringer Ingelheim

Recruiting

A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer

Neuroendocrine Neoplasms | Small Cell Lung Carcinoma (SCLC)

Netherlands
University Medical Center Groningen

Completed

89Zr-AMG211 PET Imaging Study

Advanced Gastrointestinal Cancer

Netherlands
Memorial Sloan Kettering Cancer Center
United States Department of Defense; Genentech, Inc.

Completed

Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?

Breast Cancer Metastases | HER2 Positive Breast

United States
Radboud University Medical Center
ImaginAb, Inc.

Recruiting

CD8+ T-cell PET/CT Imaging in COVID-19 Patients (Tangelo)

PET Imaging | Lymphopenia Due to COVID-19 | T-cell

Netherlands
University Medical Center Groningen
Genzyme, a Sanofi Company

Completed

Safety and Imaging Study of GC1008 in Glioma

Primary Brain Tumors

Netherlands
Memorial Sloan Kettering Cancer Center

Active, not recruiting

89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)

DLBCL | Large B-cell Lymphoma

United States
GlaxoSmithKline

Terminated

Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging

Amyloidosis

Sweden
University of Saskatchewan

Recruiting

Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)

Colorectal Cancer | Lung Cancer

Canada
Chongqing University Cancer Hospital

Not yet recruiting

Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer

Locally Advanced Cervical Cancer

China
GlaxoSmithKline
PRA Health Sciences for clinical study conduct.

Completed

A Positron Emission Tomography (PET) Imaging Study to Investigate the Biodistribution and Clearance of an Albumin Binding Domain Antibody (AlbudAb) GSK3128349 in Healthy Male Subjects

Drug-Related Side Effects and Adverse Reactions

Netherlands
Monopar Therapeutics

Recruiting

Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Lung Cancer | Bladder Cancer | Urothelial Carcinoma | Triple-negative Breast Cancer | Solid Tumor, Adult

Australia
Institut Cancerologie de l'Ouest
Telix Pharmaceutical; SIRIC ILIAD

Recruiting

Imaging Performance Assessment of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Metastatic Triple Negative Breast Cancer Patients (OPALESCENCE)

Triple Negative Breast Cancer

France
Memorial Sloan Kettering Cancer Center
BioNTech SE

Active, not recruiting

Study of a New Technique for Imaging Pancreatic Cancer

Pancreatic Cancer | Tumors That Express CA19-9

United States
Millennium Pharmaceuticals, Inc.

Terminated

A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)

Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies

United States
GlaxoSmithKline

Completed

Immuno Positron Emission Tomography Study of GSK2849330 in Subjects With Human Epidermal Growth Factor Receptor 3-Positive Solid Tumors

Neoplasms | Cancer

Netherlands

Search clinical trials for: 89Zr-KN035

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations